

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated Wednesday, June 24, 2020 (the “**Prospectus**”) issued by Honliv Healthcare Management Group Company Limited (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered. This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.



## Honliv Healthcare Management Group Company Limited 宏力醫療管理集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9906)

### END OF STABILIZATION PERIOD, STABILIZING ACTIONS AND LAPSE OF OVER-ALLOTMENT OPTION

#### STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on July 30, 2020, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The stabilizing actions undertaken by the Stabilizing Manager, its affiliates or any person acting for it during the stabilization period are set out below:

- (i) over-allocation of an aggregate of 4,408,000 Shares in the International Offering, representing approximately 2.94% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option);
- (ii) the borrowing of an aggregate of 4,408,000 Shares by the Stabilizing Manager from Sunny Rock pursuant to the Stock Borrowing Agreement to cover the over allocation in the International Offering; and

- (iii) the successive purchases of an aggregate of 4,408,000 Shares in the price range of HK\$2.01 to HK\$2.10 per Share (exclusive of brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilization period, representing approximately 2.94% of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option.

The last purchase made by the Stabilizing Manager or its agent on the market during the course of the stabilization period was on July 28, 2020 at the price of HK\$2.08 per Share (excluding brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

## **LAPSE OF OVER-ALLOTMENT OPTION**

The Company announces that the Over-allotment Option had not been exercised by BOCOM Securities (on behalf of the International Underwriters) during the stabilization period and lapsed on Thursday, July 30, 2020. Accordingly, no Shares were or will be issued under the Over-allotment Option.

## **PUBLIC FLOAT**

Immediately after the end of the stabilization period, the Company will continue to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules.

By order of the Board  
**Honliv Healthcare Management Group Company Limited**  
**Mr. Qin Yan**  
*Chairman*

Hong Kong, July 30, 2020

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Qin Yan, Dr. Teng Qingxiao and Mr. Wang Zhongtao as the executive Directors, Mr. Qin Hongchao as the non-executive Director and Mr. Zhao Chun, Mr. Sun Jigang and Mr. Jiang Tianfan as the independent non-executive Directors.*

*This announcement is available for viewing on the website of the Company at [www.honlivhp.com](http://www.honlivhp.com) and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).*